What is HC Wainwright’s Estimate for APLS Q1 Earnings?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Analysts at HC Wainwright lifted their Q1 2025 EPS estimates for Apellis Pharmaceuticals in a research report issued on Monday, March 3rd. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings of ($0.47) per share for the quarter, up from their prior estimate of ($0.55). HC Wainwright has a “Buy” rating and a $57.00 price objective on the stock. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.70) per share. HC Wainwright also issued estimates for Apellis Pharmaceuticals’ Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.42) EPS, FY2026 earnings at ($0.41) EPS and FY2027 earnings at $0.95 EPS.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings data on Friday, February 28th. The company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.08. The business had revenue of $212.50 million for the quarter, compared to analyst estimates of $197.92 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The firm’s revenue for the quarter was up 45.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.73) earnings per share.

Other analysts have also issued research reports about the stock. Robert W. Baird cut their price objective on shares of Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating on the stock in a research report on Thursday, November 7th. Wells Fargo & Company cut their price objective on shares of Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 6th. Bank of America cut their price objective on shares of Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. JPMorgan Chase & Co. boosted their target price on shares of Apellis Pharmaceuticals from $50.00 to $54.00 and gave the stock an “overweight” rating in a report on Tuesday. Finally, Wedbush lowered their target price on shares of Apellis Pharmaceuticals from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Monday. Eight analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $45.53.

Apellis Pharmaceuticals Stock Performance

Shares of APLS stock opened at $26.00 on Wednesday. The company’s fifty day simple moving average is $29.53 and its 200-day simple moving average is $31.30. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91. The firm has a market cap of $3.23 billion, a PE ratio of -12.81 and a beta of 0.93. Apellis Pharmaceuticals has a 12 month low of $23.77 and a 12 month high of $64.33.

Insider Buying and Selling at Apellis Pharmaceuticals

In related news, insider Caroline Baumal sold 2,816 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $33.81, for a total value of $95,208.96. Following the transaction, the insider now directly owns 55,560 shares in the company, valued at approximately $1,878,483.60. This represents a 4.82 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Cedric Francois sold 6,247 shares of the company’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $28.70, for a total transaction of $179,288.90. Following the completion of the transaction, the chief executive officer now owns 307,415 shares in the company, valued at $8,822,810.50. This trade represents a 1.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 60,365 shares of company stock worth $1,810,479 over the last ninety days. Insiders own 6.80% of the company’s stock.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. grew its stake in shares of Apellis Pharmaceuticals by 23.3% in the third quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company’s stock valued at $112,036,000 after acquiring an additional 735,160 shares in the last quarter. AlphaCentric Advisors LLC bought a new stake in Apellis Pharmaceuticals during the third quarter worth about $1,370,000. GSA Capital Partners LLP bought a new stake in Apellis Pharmaceuticals during the third quarter worth about $824,000. BNP Paribas Financial Markets lifted its position in Apellis Pharmaceuticals by 52.9% during the third quarter. BNP Paribas Financial Markets now owns 159,700 shares of the company’s stock worth $4,606,000 after purchasing an additional 55,282 shares during the period. Finally, Old West Investment Management LLC bought a new stake in Apellis Pharmaceuticals during the third quarter worth about $2,953,000. 96.29% of the stock is currently owned by institutional investors and hedge funds.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).